Clinical Trial Update: IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ALT-803 administered subcutaneously after initial ALT-803 treatment for ovarian cancer, fallopian tube cancer, and primary peritoneal c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• ALT-803 (Interleukin-15 super-agonist)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-05-06